Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Payables (2016 - 2025)

Historic Payables for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $9.1 million.

  • Catalyst Pharmaceuticals' Payables fell 2133.53% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year decrease of 2133.53%. This contributed to the annual value of $16.6 million for FY2024, which is 1215.28% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Payables of $9.1 million as of Q3 2025, which was down 2133.53% from $5.5 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Payables high stood at $16.6 million for Q4 2024, and its period low was $2.3 million during Q2 2022.
  • For the 5-year period, Catalyst Pharmaceuticals' Payables averaged around $6.5 million, with its median value being $4.6 million (2023).
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Payables plummeted by 4962.77% in 2021, and later soared by 27220.13% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Payables (Quarter) stood at $2.8 million in 2021, then surged by 43.61% to $4.0 million in 2022, then soared by 272.2% to $14.8 million in 2023, then increased by 12.15% to $16.6 million in 2024, then crashed by 45.18% to $9.1 million in 2025.
  • Its Payables stands at $9.1 million for Q3 2025, versus $5.5 million for Q2 2025 and $11.2 million for Q1 2025.